Key Highlights
- CVS Group plc (LSE:CVSG) gained 3.04% on 6 October 2026, extending its recovery after full-year results in late September.
- The CMA published its final remedies order on 22 September 2026, ending a long regulatory process that had weighed on the sector.
- FY26 Revenue rose 5.9% to £712.8 million, with like-for-like sales growth improving to 2.1% from 0.2%.
- Australian revenue jumped from £52.1 million to £79.1 million and now represents around 11% of the group.
- A £50 million share buyback is underway, and the new financial year has started with positive like-for-like growth.
CVS Group plc (LSE:CVSG) Builds on Post-Results Momentum
CVS Group plc (LSE:CVSG) rose 3.04% on Tuesday, 6 October 2026, as investors continued to warm to the UK and Australian veterinary services group. The gain added to a positive reaction to the company's full-year results on 24 September, which were delivered alongside the final conclusion of the Competition and Markets Authority's investigation into the veterinary market.
The broader market backdrop was supportive, with UK equities lifted by gains on Wall Street and expectations that US interest rates will remain on hold. Defensive Growth Stocks with improving fundamentals, such as CVS Group plc (LSE:CVSG), have attracted renewed buying interest.
Why CVS Group plc (LSE:CVSG) Is in Focus
The single biggest reason investors are watching CVS Group plc (LSE:CVSG) is regulatory clarity. The CMA's market investigation into veterinary services had hung over the sector for a long time, acting as a brake on UK consolidation and weighing on share prices. The CMA published its final decision in March 2026 and its final remedies order on 22 September 2026. The final outcome was widely seen as less punitive than feared, and CVS said it had already implemented most of the required remedies, including measures around transparent pricing and branding.
With the process concluded, management can refocus on growth. The company said it was confident of a return to UK acquisitions, and it has already exchanged contracts to acquire a two-site UK practice employing nine full-time equivalent vets for an initial consideration of £15 million. That marks the first meaningful UK deal activity since the investigation began.
Solid Full-Year Results
For the year ended 30 June 2026, CVS Group plc (LSE:CVSG) reported revenue growth of 5.9% to £712.8 million. Like-for-like sales increased 2.1%, a clear improvement from 0.2% the previous year, despite a softer UK economic backdrop. Adjusted EBITDA was around £141.5 million, in line with market expectations, with the Margin maintained at 19.9%, within the company's guidance range of 19% to 23%.
Like-for-like growth remains below the company's medium-term target range of 4% to 8%, so investors will be watching for further acceleration. The company has invested in clinics, digital tools and its customer proposition, and launched CVS Vets as a dual Brand alongside local practice names to build awareness and trust.
Australia Becomes a Growth Engine
Australian expansion is increasingly important to the Investment case. Revenue from Australia rose more than 50% to £79.1 million, from £52.1 million, and now represents around 11% of group revenue, up from 7%. During the year, CVS acquired six Australian practices covering 14 sites for combined initial consideration of £43.3 million. Management said acquired practices are outperforming business plans, with synergies enhancing results, and that there is a strong pipeline of further opportunities in Australia.
Buyback and Balance Sheet Strength
CVS Group plc (LSE:CVSG) is returning Capital to shareholders through a £50 million share buyback. The company also has around £150 million of undrawn facilities and cash, giving it flexibility to fund acquisitions in both the UK and Australia. Capital Expenditure was kept disciplined at around 5% of revenue. Market forecasts point to FY27 sales of around £747 million and underlying EBITDA of around £150 million.
One open issue is chief executive succession, which remains unresolved. Investors will be watching for an announcement on leadership, as a strong appointment could further boost confidence.
Why the Stock Moved Up Today
The 3.04% gain on 6 October reflected continued buying after the CMA clarity and solid results, support from the share buyback and a positive day for UK mid-caps. The company's comment that the new financial year has started solidly with positive like-for-like sales growth has also reassured investors that momentum is being maintained.
What Investors Are Watching Next
The next key event will be the AGM trading update, typically held in November, which will show how like-for-like sales and margins are developing in the new financial year. Investors will also watch for UK Acquisition activity, further Australian deals, the CEO appointment and any updates on reform of the Veterinary Surgeons Act. Risks include weak consumer spending, staff shortages in the veterinary profession and implementation costs from regulatory remedies. Nevertheless, with regulatory uncertainty lifted, CVS Group plc (LSE:CVSG) is well positioned for a re-rating.






Please wait processing your request...